Dr. Lui Franciosi reports

HEALTH CANADA'S IMPROVED PROCESSING OF ACMPR APPLICATIONS AND THE APPLICATION STATUS OF VERITAS' SUBSIDIARY, SECHELT ORGANIC MARIJUANA CORP.

Veritas Pharma Inc., as an ACMPR applicant, would like to notify its investors that Health Canada is introducing several improvements that aim to streamline the ACMPR licensing process.

Veritas's wholly owned subsidiary, Sechelt Organic Marijuana Corp., is in the process of applying for a Health Canada ACMPR licence. On July 4, 2014, Sechelt filed an application with Health Canada for said licence. Its application is awaiting the issuance of a licence to produce.

Effective immediately, Health Canada is implementing the following measures:

• Increasing the department's capacity to review and process applications;

• Health Canada is allocating more resources to streamline the processing of applications to produce cannabis for medical purposes. There are currently 187 applications at the review stage. Sechelt is currently one of the 187 applications in what was previously known as the "review stage";

• Undertaking some stages of the review of the application concurrently;

• The detailed review stage of processing applications will now happen at the same time as the personnel security screening process. Historically, the review stage did not begin until the security screening of key personnel is complete, which can lengthen the time to process the application. Sechelt has already cleared the security screening process;

• Permitting licensed producers to manage production on the basis of their vault capacity;

• Licensed producers will be permitted to increase cannabis production within their existing facility to the maximum they are authorized to store, based on the capacity and security level of their vault(s) or safe(s). This will allow licensed producers to better manage production as necessary to meet demand;

• In addition, licensed producers will be able to store low-value cannabis waste products (such as leaves) in a secure area and will no longer need to keep these products in a secure vault or safe, thereby creating more room for storage of finished cannabis products and enabling increased production;

• Authorizing longer validity periods for licences and security clearances in accordance with the regulations;

• New licences that are issued, and existing licences that are renewed for licensed producers with a good compliance record, may now be valid for the full three years allowed in the regulations;

• Streamlining the review and approval of applications to modify or expand a production facility for licensed producers with a record of good compliance with the ACMPR;

• Where a licensed producer has a good compliance record and the proposed modification or expansion is straightforward, is materially similar to an existing room or facility and it falls within an existing security perimeter (such as a fence), applications for a production site modification or expansion may be approved following a successful application review. The physical inspection of the site modification or expansion would then occur during the regular facility inspection rather than before approval. Sechelt views this as a very positive development as the previous iteration of the rules did not lay out a direction for scaling cultivation as appropriately.

Health Canada will continue to inspect all facilities before cultivation begins and before a licence to sell products to the public is issued. Henceforth, Health Canada will schedule this first inspection after it has determined an application meets the regulatory requirements and it has issued the licence to cultivate and once the producer is ready to initiate production in its facility.

Veritas chief executive officer, Dr. Lui Franciosi, commented: "Our goal is to create shareholder value. To achieve this, we plan to create the most effective disease-specific strains of cannabis, and to provide conclusive scientific evidence so doctors and patients alike can recommend and use our proprietary strains with confidence. A key portion of the strategy is to produce high-quality, consistent cannabis plants and Sechelt, once licensed, will provide us with the perfect platform through which to facilitate the realization of the company's vision. The company is excited that Health Canada seems to be accelerating their rate of approvals, passing three in the previous 60 days, as it bodes well for our Sechelt application."

About Veritas Pharma Inc.

Veritas Pharma is an emerging-stage pharmaceutical and intellectual property development company which, through Cannevert Therapeutics, is advancing the science behind medical cannabis.